Latest News & Features
Medtech
A handful of high-profile disputes over medical use patents have been decided in Japan, as Osamu Yamamoto of Yuasa and Hara reports. 21 June 2017
Asia
India’s regulatory environment surrounding pharmaceuticals and medical devices needs to evolve in order to unlock the industries’ true potential, says Kirit Javali of Jafa & Javali. 15 June 2017
Europe
A new EU regulation on implantable medical devices takes steps to acknowledge that patient outcomes and safety are primary goals, but the transition to the new system might not be easy for industry stakeholders, says Jo Emmett of Premier Research. 13 June 2017
Americas
The Brazilian Patent and Trademark Office has implemented several fast-track examination programmes. Ana Paula Jardim and Andréa Granthon of Luiz Leonardos report on the effectiveness of one of them, the Green Patent Programme. 13 June 2017
article
Erica Pascal of DLA Piper investigates the patentability of machine learning and its outcomes, and the complex issues that may arise. 7 June 2017
article
Medical technology companies should not be left out of discussions in Europe about modernising the system for supplementary protection certificates, argues Allison Sadick of Pinsent Masons. 19 May 2017
Americas
A disagreement over how pharma patents in Brazil are examined seems to have come to an end, as Breno Souza, Luisa Rezende and Silvia Costa of Clarke Modet & Co Brazil report. 25 April 2017
Biotechnology
European developments surrounding the patentability of plants and animals have become rather political, but there are ways for patentees to mitigate the effects of political influence over the patenting process, writes Jane Wainwright of Potter Clarkson. 4 April 2017
Americas
A new law on supplementary protection certificates will be implemented on April 1, with the application, prosecution and maintenance of SPCs taking centre stage. José Manuel González
of Clarke, Modet & Co reports. 27 March 2017
Americas
President Trump’s decision to pull the US out of the Trans-Pacific Partnership trade deal may have particularly pernicious consequences for the pharmaceutical and biotechnology industries, writes Kevin Noonan of McDonnell Boehnen Hulbert & Berghoff. 15 March 2017